Our data suggest that PTEN levels could be increased due to a strong impairment of FMRP binding and activity by mutant FUS, possibly extending the applicability of this therapeutic approach to FUS-ALS. The gene discussed is FMR1; the disease is amyotrophic lateral sclerosis.